European Leukemia Trial Registry
Trial: TOR-AML

More Details
Short Title TOR-AML
Trialgroup SAL
Type of Trial multicentric, randomized, prospective, double-blind, double-group
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age > 60 years
Status Follow up
Start of Recruitment 23.05.2012
Leader Brandts, Prof. Dr. med., Christian

Study coordinator
Wolf, Andrea
Tel: +49 (0)69 63016429
Fax: +49 (0)69 63017463

Study assistance
Kämpf, Sophia
Tel: +49 (0)69 630106663

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
created 05.06.2012 Janina Rosemeier
changed 12.10.2016 Eva-Maria Ableidinger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |